- Advanced search
- Immuno Portal
- Malaria Portal
|Approved drug?||Yes (FDA & EMA (2019))|
|International Nonproprietary Names|
|ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®|
|Risankizumab (research code BI 655066) is a humanised monoclonal antibody targeting interleukin 23A (IL-23A) . It was developed through collaboration between Boehringer Ingelheim and AbbVie for the treatment of autoinflammatory diseases.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
|GtoPdb PubChem SID||310264703|
|Search PubMed clinical trials||risankizumab|
|Search PubMed titles||risankizumab|
|Search PubMed titles/abstracts||risankizumab|